<DOC>
	<DOCNO>NCT00092053</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety investigational drug postmenopausal woman osteoporosis . The primary hypothesis study postmenopausal woman osteoporosis , oral monthly ibandronate , dose 100 mg 150 mg , achieve persistence reduction bone resorption throughout monthly dose interval , demonstrate large change serum carboxyterminal crosslinked telopeptide Type I collagen ( CTX-I ) log-transformed fraction baseline four week post dose compare one week post dose , third month treatment , participant take ibandronate participant take placebo .</brief_summary>
	<brief_title>Study Investigational Drug Osteoporosis ( MK-0217-908 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>postmenopausal least 3 year , osteoporosis follow site : [ BMD &gt; 2.0 standard deviation young normal mean bone mass hip trochanter , PA lumbar spine ( L1 L4 ) , total hip , femoral neck base normative database provide individual manufacturer ] . willing take studysupplied calcium vitamin D supplement ( equivalent ) discontinue nonstudy calcium supplement runin period duration study . pregnant lactating , childbearing potential . participate another therapeutic trial investigational compound within 30 day randomization . history hypersensitivity component ibandronate tablet hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . abnormality esophagus delay esophageal empty stricture achalasia . unable stand sit upright least 60 minute month . current use illicit drug , history drug alcohol abuse within past five year . follow : hypocalcemia ; severe malabsorption syndrome ; moderate severe hypertension uncontrolled ; new onset angina myocardial infarction within six month entry study ; evidence impair renal function ; organ transplantation ; significant end organ disease ( genitourinary , cardiovascular , endocrine , hepatic , psychiatric , renal , hematologic , pulmonary ) . history evidence metabolic bone disease ( postmenopausal bone loss ) . clinical fracture past year . receive receive treatment prior randomization might influence bone turnover . receive expected receive course study medication ( study medication ) might alter bone calcium metabolism , include Vitamin A excess 10,000 IU per day Vitamin D excess 5000 IU per day , calcitonin , phenytoin , heparin , lithium .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>